A phase I clinical trial using intravenous SynKIR-110 is registered in the United States (NCT05568680) for patients with mesothelin-expressing ovarian cancer, mesothelioma, and cholangiocarcinoma, though the status is currently unknown. The gene discussed is MSLN; the disease is ovarian cancer.